Literature DB >> 15469052

A mechanism-based understanding of bone cancer pain.

Patrick W Mantyh1.   

Abstract

Although bone cancer pain can be severe and is relatively common, as it frequently arises from metastases from breast, prostate and lung tumours, relatively little is known about the basic mechanisms that generate and maintain this chronic pain. To begin to define the mechanisms that give rise to bone cancer pain, we developed a mouse model using the intramedullary injection and containment of osteolytic sarcoma cells into the mouse femur. These tumour cells induced bone destruction as well as ongoing and movement evoked pain behaviours similar to that found in patients with bone cancer pain. In addition, there was a significant neurochemical reorganization of sensory neurons that innervate the tumour bearing bone as well as in the spinal cord segments that received sensory input from the cancerous bone. This reorganization generated a neurochemical signature of bone cancer pain that was different from that observed in mouse models of chronic neuropathic or inflammatory pain. These data suggest that there is an inflammatory, neuropathic and tumorigenic component to bone cancer pain. Therefore defining when and how these different components drive bone cancer pain may allow the development of more selective analgesic agents to treat this chronic pain state.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15469052

Source DB:  PubMed          Journal:  Novartis Found Symp        ISSN: 1528-2511


  11 in total

1.  Study of the analgesic activities, chronic toxicity and addictive potential of Jia-Yuan-Qing pill in rats.

Authors:  Y E Tian; Li-Rong Teng; Zhen-Zuo Wang; Min Zhao; Qing-Fan Meng; Jia-Hui Lu; Jian-Ming Tian; Wei-Wei Zhang; Xiaoyi Zheng; D I Wang; LE-Sheng Teng
Journal:  Exp Ther Med       Date:  2015-04-15       Impact factor: 2.447

2.  Image-guided percutaneous ablation of bone and soft tissue tumors.

Authors:  A Nicholas Kurup; Matthew R Callstrom
Journal:  Semin Intervent Radiol       Date:  2010-09       Impact factor: 1.513

Review 3.  Animal models of cancer pain.

Authors:  Cholawat Pacharinsak; Alvin Beitz
Journal:  Comp Med       Date:  2008-06       Impact factor: 0.982

4.  Use of non-opioid analgesics as adjuvants to opioid analgesia for cancer pain management in an inpatient palliative unit: does this improve pain control and reduce opioid requirements?

Authors:  Shivani Shinde; Pamela Gordon; Prashant Sharma; James Gross; Mellar P Davis
Journal:  Support Care Cancer       Date:  2014-08-29       Impact factor: 3.603

Review 5.  An overview of animal models of pain: disease models and outcome measures.

Authors:  Nicholas S Gregory; Amber L Harris; Caleb R Robinson; Patrick M Dougherty; Perry N Fuchs; Kathleen A Sluka
Journal:  J Pain       Date:  2013-09-12       Impact factor: 5.820

6.  GDNF, Neurturin, and Artemin Activate and Sensitize Bone Afferent Neurons and Contribute to Inflammatory Bone Pain.

Authors:  Sara Nencini; Mitchell Ringuet; Dong-Hyun Kim; Claire Greenhill; Jason J Ivanusic
Journal:  J Neurosci       Date:  2018-04-30       Impact factor: 6.167

Review 7.  Effect of bisphosphonates on pain and quality of life in patients with bone metastases.

Authors:  Luis Costa; Pierre P Major
Journal:  Nat Clin Pract Oncol       Date:  2009-02-03

8.  Involvement of lysophosphatidic acid in bone cancer pain by potentiation of TRPV1 via PKCε pathway in dorsal root ganglion neurons.

Authors:  Hai-Li Pan; Yu-Qiu Zhang; Zhi-Qi Zhao
Journal:  Mol Pain       Date:  2010-12-01       Impact factor: 3.395

9.  Cancer Pain: A Critical Review of Mechanism-based Classification and Physical Therapy Management in Palliative Care.

Authors:  Senthil P Kumar
Journal:  Indian J Palliat Care       Date:  2011-05

10.  Genome-wide identification and functional analyses of microRNA signatures associated with cancer pain.

Authors:  Kiran Kumar Bali; Deepitha Selvaraj; Venkata P Satagopam; Jianning Lu; Reinhard Schneider; Rohini Kuner
Journal:  EMBO Mol Med       Date:  2013-10-18       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.